Dr. William Williams reports

BRIACELL ANNOUNCES RESCHEDULING OF ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS TO FEBRUARY 5, 2025

Briacell Therapeutics Corp.'s annual general meeting of shareholders, which was originally scheduled to be held on Thursday, Jan. 23, 2025, has been rescheduled. The meeting is now scheduled to be held on Wednesday, Feb. 5, 2025, at 9 a.m. ET at suite 3400, One First Canadian Place, Toronto, Ont., M5X 1A4. The record date for the meeting, Dec. 9, 2024, is unchanged and applies to the postponed meeting. The meeting has been postponed due to delays stemming from the disruption in postal service in Canada, and to provide further time to solicit proxies from the company's shareholders.

Shareholders who have already cast their votes do not need to take any action, unless they wish to change or revoke their prior proxy or voting instructions, and their votes will be counted at the postponed meeting. For shareholders who have not yet cast their votes, the company urges them to vote their shares now, so they can be tabulated prior to the postponed meeting. completed and signed proxies and NOBO VIFs must be received by Computershare by 9 a.m. ET on Feb. 3, 2025.

The company filed its proxy statement for the meeting on Dec. 17, 2024: (i) under the company's profile on EDGAR with the Securities and Exchange Commission, (ii) under the company's profile on SEDAR+ and (iii) on the company's website. The proxy statement should be read in conjunction with this notice. To the extent information in this notice updates or conflicts with information contained in the proxy statement, the information in this notice is the more current information. Shareholders are urged to read the proxy statement (including any amendments or supplements thereto) filed by Briacell and any other relevant meeting documents carefully and in their entirety because they contain or may contain important information about any solicitation.

The meeting will address the following: receipt of audited financial statements and auditor's report, election of directors for the coming year, and appointment of the auditor and setting its remuneration. Briacell's board of directors unanimously recommends that you vote for the proposals identified in the company's proxy statement for the meeting. Institutional shareholder Services Inc. (ISS) has released its recommendation that shareholders vote for the proposals, as well.

How shareholders can vote

Registered shareholders are shareholders who hold their shares directly in the company, and not through a brokerage account or depository company. Registered shareholders can call Computershare Shareholder Services at 1-800-564-6253 (Canada/United States) or for overseas holders, call direct dial number 1-514-982-7555 (Monday to Friday, 8:30 a.m. to 8 p.m. ET) to request their voting control numbers.

Beneficial shareholders are shareholders who hold their investment through a brokerage house, depository company or other intermediary. There are two types of beneficial owners: (i) those who object to their identity being made known to the issuers of securities which they own (objecting beneficial owners or OBOs), and (ii) those who do not object to their identity being made known to the issuers of securities which they own (non-objecting beneficial owners or NOBOs). The company has arranged to send meeting materials directly to NOBOs. NOBOs may submit their votes by completing the voting instruction form (VIF) available on the company's website and sending the completed VIF to Computershare by e-mail at service@computershare.com. NOBOs can also contact Computershare at 1-800-564-6253 to request their voting control numbers and instructions. OBOs should contact their brokerage house or depository company or other intermediary and ask to obtain their voting control number and instructions.

Shareholders are strongly encouraged to vote via telephone or Internet at:

On-line:  Investor Vote website

Toll-free telephone:  1-866-732-VOTE (8683)

Investor questions and assistance

Shareholders who have questions or require assistance with voting their proxy may contact Briacell's proxy solicitation agent, Sodali, at:

North American toll-free number:   1-888-444-0591

Outside North America (collect calls accepted):   1-289-695-3075

E-mail:  assistance@investor.sodali.com

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.